1921
Volume 93, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

We retrospectively analyzed the background, clinical features, and treatment response of 50 cases of imported loiasis who presented between 2000 and 2014 to the Hospital for Tropical Diseases (HTD), London, United Kingdom. Of them, 29 were migrants from, and 21 were visitors to, countries where the disease is endemic. Clinical features differed between these groups. Migrants experienced fewer Calabar swellings (odds ratio [OR] = 0.12), more eye worm (OR = 3.4), more microfilaremia (OR = 3.5), lower filarial antibody levels, and lower eosinophil counts ( < 0.05 for all tests). Among 46 patients who were started on treatment at HTD, 33 (72%) received diethylcarbamazine (DEC) monotherapy as first-line treatment, and among 26 patients who were followed up after treatment, seven (27%) needed a second course of treatment. There were 46 courses of treatment with DEC, and 20 (43%) of them had reactions. All patients with microfilaremia > 3,000 microfilariae/mL and all those with an elevated C-reactive protein (CRP) (≥ 5 mg/L) before treatment had reactions ( = 0.10 and = 0.01, respectively). These data suggest that monotherapy with DEC may not be the optimal treatment for patients with loiasis, particularly for those with a high microfilarial load.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0214
2015-09-02
2017-11-20
Loading full text...

Full text loading...

/deliver/fulltext/14761645/93/3/607.html?itemId=/content/journals/10.4269/ajtmh.15-0214&mimeType=html&fmt=ahah

References

  1. Zoure HGM, Wanji S, Noma M, Amazigo UV, Diggle PJ, Tekle AH, Remme JHF, , 2011. The geographic distribution of Loa loa in Africa: results of large-scale implementation of the rapid assessment procedure for loiasis (RAPLOA). PLoS Negl Trop Dis 5: e1210.[Crossref]
  2. Metzger WG, Mordmuller B, , 2014. Loa loa—does it deserve to be neglected? Lancet Infect Dis 14: 353357.[Crossref]
  3. Boussinesq M, , 2006. Loiasis. Ann Trop Med Parasitol 100: 715731.[Crossref]
  4. Lipner EM, Law MA, Barnett E, Keystone JS, von Sonnenburg F, Loutan L, Prevots DR, Klion AD, Nutman TB, GeoSentinel Surveillance Network; , 2007. Filariasis in travelers presenting to the GeoSentinel Surveillance Network. PLoS Negl Trop Dis 1: e88.[Crossref]
  5. Churchill DR, Morris C, Fakoya A, Wright SG, Davidson RN, , 1996. Clinical and laboratory features of patients with loiasis (Loa loa filariasis) in the UK. J Infect 33: 103109.[Crossref]
  6. Gantois N, Rapp C, Gautret P, Ficko C, Savini H, Larreche S, Saidi R, Crevon L, Simon F, , 2013. Imported loiasis in France: a retrospective analysis of 47 cases. Travel Med Infect Dis 11: 366373.[Crossref]
  7. Klion AD, Massougbodji A, Sadeler BC, Ottesen EA, Nutman TB, , 1991. Loiasis in endemic and nonendemic populations: immunologically mediated differences in clinical presentation. J Infect Dis 163: 13181325.[Crossref]
  8. Gobbi F, Postiglione C, Angheben A, Marocco S, Monteiro G, Buonfrate D, Mascarello M, Gobbo M, Boussinesq M, Bisoffi Z, , 2014. Imported loiasis in Italy: an analysis of 100 cases. Travel Med Infect Dis 12: 713717.[Crossref]
  9. Nutman TB, Reese W, Poindexter RW, Ottesen EA, , 1988. Immunologic correlates of the hyperresponsive syndrome of loiasis. J Infect Dis 157: 544550.[Crossref]
  10. Wahl G, Georges A, , 1995. Current knowledge on the epidemiology, diagnosis, immunology, and treatment of loiasis. Trop Med Parasitol 46: 287291.
  11. Gardon J, Gardon-Wendel N, Ngangue D, Kamgno J, Chippaux J-P, Boussinesq M, , 1997. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. Lancet 350: 1822.[Crossref]
  12. Carme B, Boulesteix J, Boutes H, Puruehnce M, , 1991. Five cases of encephalitis during treatment of loiasis with diethylcarbamazine. Am J Trop Med Hyg 44: 684690.
  13. Padgett JJ, Jacobsen KH, , 2008. Loiasis: African eye worm. Trans R Soc Trop Med Hyg 102: 983989.[Crossref]
  14. Boussinesq M, , 2012. Loiasis: new epidemiologic insights and proposed treatment strategy. J Travel Med 19: 140143.[Crossref]
  15. Takougang I, Meli J, Lamlenn S, Tatah PN, Ntep M, , 2007. Loiasis—a neglected and under-estimated affliction: endemicity, morbidity and perceptions in eastern Cameroon. Ann Trop Med Parasitol 101: 151160.[Crossref]
  16. Ali S, Fisher M, Juckett G, , 2008. The African eye worm: a case report and review. J Travel Med 15: 5052.[Crossref]
  17. Nutman TB, Miller KD, Mulligan M, Ottesen EA, , 1986. Loa loa infection in temporary residents of endemic regions: recognition of a hyperresponsive syndrome with characteristic clinical manifestations. J Infect Dis 154: 1018.[Crossref]
  18. Klion AD, Ottesen EA, Nutman TB, , 1994. Effectiveness of diethylcarbamazine in treating loiasis acquired by expatriate visitors to endemic regions: long-term follow-up. J Infect Dis 169: 604610.[Crossref]
  19. Antinori S, Schifanella L, Million M, Galimberti L, Ferraris L, Mandia L, Trabucchi G, Cacioppo V, Monaco G, Tosoni A, Brouqui P, Gismondo MR, Giuliani G, Corbellino M, , 2012. Imported Loa loa filariasis: three cases and a review of cases reported in non-endemic countries in the past 25 years. Int J Infect Dis 16: e649e662.[Crossref]
  20. Ghys C, Morissens M, Rozen L, Karmali R, Theunissen C, , 2012. Loiasis with pleural and peritoneal involvement. J Travel Med 19: 186188.[Crossref]
  21. Boussinesq M, Gardon J, Gardon-Wendel N, Kamgno J, Ngoumou P, Chippaux J-P, , 1998. Three probable cases of Loa loa encephalopathy following ivermectin treatment for onchocerciasis. Am J Trop Med Hyg 58: 461469.
  22. Twum-Danso N, , 2003. Loa loa encephalopathy temporally related to ivermectin administration reported from onchocerciasis mass treatment programs from 1989 to 2001: implications for the future. Filaria J 2: S7.[Crossref]
  23. Kamgno J, Pion SD, Tejiokem MC, Twum-Danso NA, Thylefors B, Boussinesq M, , 2007. Randomized, controlled, double-blind trial with ivermectin on Loa loa microfilaraemia: efficacy of a low dose (approximately 25 microg/kg) versus current standard dose (150 microg/kg). Trans R Soc Trop Med Hyg 101: 777785.[Crossref]
  24. Boussinesq M, Gardon J, Gardon-Wendel N, Chippaux J, , 2003. Clinical picture, epidemiology, and outcome of Loa-associated adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon. Filaria J 2: S4.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0214
Loading
/content/journals/10.4269/ajtmh.15-0214
Loading

Data & Media loading...

  • Received : 18 Mar 2015
  • Accepted : 05 May 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error